In addition, Li and colleagues have demonstrated that exosomes-derived from gefitinib-treated EGFR-mutant human NSCLC PC9 cell line decrease the antitumor effects of cisplatin, and that pharmacological inhibition of exosomes secretion resulted in a modest synergistic effect of cisplatin and gefitinib combination [62]. Here, EGFR is linked to non-small cell lung carcinoma.